Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal curcumin (SignPath Pharma)
- Development stage
- Phase 2
- Lead developer
- SignPath Pharma
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LipoCurc is a liposomal formulation of curcumin developed by SignPath Pharma to overcome the poor aqueous solubility and low bioavailability of free curcumin. Curcumin is a natural polyphenol that exhibits pleiotropic anti-cancer activities by modulating various molecular targets, most notably inhibiting the transcription factors NF-κB and STAT3, which are key drivers of inflammation, survival, and proliferation in glioma cells. The liposomal delivery system (SPP404) is designed to enhance systemic exposure and facilitate the crossing of the blood-brain barrier. LipoCurc is currently being investigated in Phase I/II clinical trials in combination with standard-of-care radiation and temozolomide for the treatment of newly diagnosed high-grade gliomas, where it aims to sensitize tumor cells to therapy and improve patient outcomes.
- Brand names
- LipoCurc
- Other names
- Liposomal Curcumin
02
Targets
DNMT (DNA methyltransferase)HDAC (HDAC family)NF-κBPTGS2 (Prostaglandin-Endoperoxide Synthase 2)AKT (RAC-alpha serine/threonine-protein kinase)STAT3 (Signal Transducer and Activator of Transcription 3)TNFA (Tumor necrosis factor alpha (soluble))VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on liposomal curcumin (SignPath Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal curcumin (SignPath Pharma).